Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies

INTRODUCTION: To examine pooled efficacy data from three, large phase III studies comparing mirabegron (50 and 100 mg) with placebo, and pooled safety data including additional mirabegron 25 mg and tolterodine extended release (ER) 4 mg results. METHODS: This prespecified pooled analysis of three ra...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Nitti, V W, Khullar, V, Kerrebroeck, P, Herschorn, S, Cambronero, J, Angulo, J C, Blauwet, M B, Dorrepaal, C, Siddiqui, E, Martin, N E
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Blackwell Publishing Ltd 2013
Aiheet:
Urology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3752932/
https://ncbi.nlm.nih.gov/pubmed/23692526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijcp.12194
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia